Abstract Number: 0507 • ACR Convergence 2021
Tocilizumab in Patients with New Onset Polymyalgia Rheumatica (PMR-SPARE) – a Phase 2/3 Randomized Controlled Trial
Background/Purpose: PMR is the second most common inflammatory rheumatic disease of people aged 50 years or older. Glucocorticoid therapy is highly effective, but many patients…Abstract Number: 0823 • ACR Convergence 2021
Pharmacokinetic and Pharmacodynamic Evaluation of a Proposed Biosimilar MSB11456 versus Both the US-licensed and EU-approved Tocilizumab: Results of a Randomized, Double-blind, Parallel-group, Single-dose Trial in Healthy Adults
Background/Purpose: Tocilizumab, a biologic disease-modifying antirheumatic drug, is a recombinant humanized monoclonal immunoglobulin G1 antibody against the interleukin-6 receptor (IL-6R). MSB11456 is a proposed biosimilar…Abstract Number: 0836 • ACR Convergence 2021
Flare After Switching from Intravenous Tocilizumab to Subcutaneous Formulation in Patients with Rheumatoid Arthritis
Background/Purpose: Interleukin-6 (IL-6) plays a key role in inflammatory and immune responses. Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody of the IL-6 receptor which…Abstract Number: 1242 • ACR Convergence 2021
Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis
Background/Purpose: To investigate sex differences in clinical response to three different biological treatments in combination with methotrexate (MTX) versus MTX plus corticosteroids (active conventional treatment;…Abstract Number: 1246 • ACR Convergence 2021
The Effect of Tocilizumab on miR-146a-5p and EMMPRIN/CD147 in Rheumatoid Arthritis Patients
Background/Purpose: Angiogenesis is an important contributor to the development of rheumatoid arthritis (RA). Tocilizumab (TCZ), an anti-IL-6 receptor antibody used in the treatment of RA…Abstract Number: 1397 • ACR Convergence 2021
Treatment of Giant Cell Arteritis with Tocilizumab: A Retrospective Cohort Study of 119 Patients
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory condition of medium- and large-sized arteries. Prospective clinical trials have demonstrated the efficacy of tocilizumab (TCZ) for…Abstract Number: 1402 • ACR Convergence 2021
Clinical, Laboratory and Imaging Outcomes in Tocilizumab-Treated Patients with Large Vessel-Giant Cell Arteritis According to Early Onset Therapy
Background/Purpose: Tocilizumab (TCZ) has shown efficacy in large vessel vasculitis (LVV)-Giant Cell Arteritis (LVV-GCA) (1-2). 18F-fluodeoxyglucose positron emission tomography (18F-FDG PET/CT) is useful to assess…Abstract Number: 1412 • ACR Convergence 2021
Effectiveness of Tocilizumab in the Visual Involvement of Giant Cell Arteritis: Multicenter Study of 471 Patients of Clinical Practice
Background/Purpose: One of the most feared complications of giant cell arteritis (GCA) is visual affection. Tocilizumab (TCZ) has demonstrated efficacy and safety in GCA. However,…Abstract Number: 1679 • ACR Convergence 2021
Effectiveness and Safety of Tocilizumab SC Every 10 Days in Patients with Rheumatoid Arthritis Who Previously Used Tocilizumab EV During the COVID 19 Pandemic at the Hospital Docente Padre Billini, Dominican Republic
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease systemic, with a prevalence 0.5 - 1% of the population, with predilection for the female sex. (1)…Abstract Number: 1870 • ACR Convergence 2021
Comparative Study on Anti-TNF vs Tocilizumab for Treatment of Refractory Uveitic Cystoid Macular Edema Due to Behcet’s Disease: Multicenter Study of 49 Patients
Background/Purpose: Posterior segment involvement is the most serious affection of uveitis in Behçet’s disease (BD), with cystoid macular edema (CME) being the leading cause of…Abstract Number: 1878 • ACR Convergence 2021
Tocilizumab in Caucasian Patients with Takayasu Arteritis: Multicenter Study of 54 Patients
Background/Purpose: Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including Takayasu arteritis (TAK) (1-3). Most evidence in TAK comes from Asian patients.…Abstract Number: 099 • 2020 Pediatric Rheumatology Symposium
Reversible Hepatotoxicity to IL-1/IL-6 Blockade in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
Background/Purpose: Treatment for systemic JIA (sJIA) complicated by macrophage activation syndrome (MAS) may involve blockade of IL-1 and IL-6. There are reports of adults with…Abstract Number: L09 • 2019 ACR/ARP Annual Meeting
A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial
Background/Purpose: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (RA) is yet to be established. The primary aim was to assess and…Abstract Number: 1244 • 2019 ACR/ARP Annual Meeting
Tocilizumab – An Effective Rescue Therapy for Refractory Unclassified Autoinflammatory Diseases in Children
Background/Purpose: Evidence based treatment options for children and adults with unclassified autoinflammatory diseases (AID) are limited. Frequently, IL-1-inhibition is primarily tried to control the severe…Abstract Number: 2682 • 2019 ACR/ARP Annual Meeting
Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution
Background/Purpose: Tocilizumab (TCZ) has proved to be effective in the management of Giant Cell Arteritis (GCA). Based on results of the GiACTA trial, it has…
ACR Meeting Abstracts